Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
Latest Information Update: 01 Mar 2023
At a glance
- Drugs Eplerenone (Primary)
- Indications Hyperaldosteronism; Hypertension
- Focus Therapeutic Use
Most Recent Events
- 24 Feb 2023 Planned End Date changed from 1 Sep 2026 to 28 Feb 2027.
- 24 Feb 2023 Planned primary completion date changed from 1 Sep 2026 to 31 Oct 2026.
- 24 Feb 2023 Status changed from not yet recruiting to recruiting.